REVIVA PHARMACEUTICALS HOLDI (RVPH) Stock Income Statement
USA - NASDAQ:RVPH - US76152G1004 - Common Stock
0.5792 USD
+0.02 (+3.28%)
0.5729 USD
-0.01 (-1.09%)
| TTM (2025-6-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | |||
| Gross Premiums Earned | null | null | null | null | null | |||
| Loss Claims | null | null | null | null | null | |||
| Deferred Policy Acquisition Expense | null | null | null | null | null | |||
| Net Interest Income | null | null | null | null | null | |||
| Non Interest Income | null | null | null | null | null | |||
| Loan Loss Provision | null | null | null | null | null | |||
| Net Interest Income after Provision | null | null | null | null | null | |||
| Non Interest Expense | null | null | null | null | null | |||
| Minority Interest Expense | null | null | null | null | null | |||
| Cost Of Goods | null | null | null | null | null | |||
| Gross Profit | null | null | null | null | null | |||
| Operating Expenses | 27.36M | 30.80M | 39.50M | 28.23M | 10.10M | |||
| Research and Development | 19.38M | 22.91M | 31.42M | 22.87M | 4.85M | |||
| Selling, General, and Administrative Expenses | 7.98M | 7.89M | 8.08M | 5.36M | 5.25M | |||
| Operating Income | -27.36M | -30.80M | -39.50M | -28.23M | -10.10M | |||
| Interest Income/Expense | 183.40K | 342.90K | 499.00K | 182.80K | -2.40K | |||
| Other Income/Expense | 81.20K | 556.70K | -239.20K | -194.70K | 1.59M | |||
| Non Recurring Items | null | null | null | null | null | |||
| Income Before Taxes | -27.09M | -29.90M | -39.24M | -28.24M | -8.52M | |||
| Income Tax | 17.90K | 19.50K | 16.90K | 20.80K | 6.00K | |||
| Net Income | -27.11M | -29.92M | -39.26M | -28.26M | -8.52M | |||
| EBITDA | null | undefined | undefined | undefined | undefined | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.6636 | -0.9 | -1.65 | -1.45 | -0.58 | |||
| Non GAAP EPS | -0.65 | -0.91 | -1.6400000000000001 | -1.25 | -0.5599999999999999 | |||
| Statistics | ||||||||
All data in USD